AzTrials
AzTrials

Pulpitis - ReversibleNCT07171229

Evaluation of Cytokines Level as an Indicator of Pulp Inflammation and Its Relation to the Success Rates of Pulpotomy in Primary Molars Affected With Proximal Versus Occlusal Decay

A study testing Pulpotomy and Measuring Cytokines level in people with Pulpitis - Reversible and Occlusal Caries, run by Cairo University at 1 site in Egypt.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

pulpotomy will be done I primary molars with occlusal or proximal decay and level of cytokines will be measured as an indicator for pulp inflammation levels Read more about this study

Who is it for?
Ages 4 to 9 years
What is being tested?
Pulpotomy and Measuring Cytokines level
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
58 participants
Where
1 siteEgypt
Study dates
1 Sep 2025to 1 Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 9 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Children with provoked pain.
  • Caries in proximal surface to the dentine full thickness.
  • Caries in occlusal surface to the dentine full thickness.
  • Radicular pulp health is verified by achieving hemostasis within eight minutes of compression using a cotton pellet with 5% sodium hypochlorite.

Who cannot join

  • Unrestorable primary molars.
  • Primary molars with spontaneous pain.
  • Medically compromised patients who have systemic disease.
  • Uncooperative children who refuse treatment.
  • Children whose parents are unwilling to place stainless steel crowns.
  • Children whose parents or caregivers refuse to participate in the study or are unable to attend follow-up visits.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Yasmin Ma Khalifa, PhD Candidate contact

+201000300634

Ymkhalifa1991@gmail.com

Egypt1 site
  • Cairo Univeristy

    Cairo

    Yasmin Magdi Khalifa, +201000300634

Other trials in Egypt

About this study

Official title: Evaluation of Cytokines Level as an Indicator of Pulp Inflammation and Its Relation to the Success Rates of Pulpotomy in Primary Molars Affected With Proximal Versus Occlusal Decay: Non-Randomized Clinical Trial

pulpotomy will be done I primary molars with occlusal or proximal decay and level of cytokines will be measured as an indicator for pulp inflammation levels

Read the detailed description

The proposed trial interventions, pulpotomy, will follow standard clinical procedural guidelines. Participants will be allocated to one of the two intervention groups only after intra-operative confirmation of pulp vitality and achievement of radicular pulp hemostasis.

Standard clinical protocol for both groups with occlusal and proximal decay:

  1. A detailed history of symptoms will be obtained, and a thorough clinical examination will be conducted.
  2. Pre-operative pain intensity will be assessed using a validated five-face visual analog scale (VAS), where children select the face that best represents their pain level.
  3. A standard pre-operative periapical radiograph will be taken, ensuring the image extends beyond the root tip and shows no distortion or processing errors.
  4. Local anesthesia will be administered, and the tooth will be isolated with a rubber dam.
  5. To minimize further bacterial contamination, carious tissues will be removed progressively, starting from the cavity periphery and then over the pulp chamber roof.
  6. Before managing the pulpal hemorrhage, a sterile cotton pellet will be placed over the pulp tissue for 30-45 s. to obtain pulpal blood samples. The specimens will be collected into heparin-coated tubes with 1 mg saline solution and stored at - 20 °C (-4.0 °F) for 6 months until the day of testing.
  7. A fresh sterile bur will be used to remove all coronal pulp tissue down to the root canal orifices, with copious water irrigation. Intra-operative assessment of pulp vitality will be conducted, with healthy vital pulp appearing as uniformly reddish-pink vascular tissue and non-vital pulp as dark avascular tissue or yellowish liquefied areas. If necrotic, the tooth will be excluded from the study, and local management protocols will be followed for treatment (Bas et al., 2024).
  8. MTA will be used as medicament of choice for pulpotomy.
  9. Once a 2-3 mm thickness is ensured, the cavity will be filled with restorative glass ionomer cement to seal it.
  10. The pulpotomy-treated tooth will be prepared to receive a full-coverage stainless steel crown (SSC) after the procedure.
Being tested
Pulpotomy, Measuring Cytokines level
Keywords
pulpotomy, cytokines

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PulpotomyProcedure or surgery

    • Local anesthesia will be administered, and the tooth will be isolated with a rubber dam.
    • To minimize further bacterial contamination, carious tissues will be removed progressively, starting from the cavity periphery and then over the pulp chamber roof.
    • Before managing the pulpal hemorrhage, a sterile cotton pellet will be placed over the pulp tissue for 30-45 s.
    • A fresh sterile bur will be used to remove all coronal pulp tissue down to the root canal orifices, with copious water irrigation
    • MTA will be used as medicament of choice for pulpotomy.
    • The pulpotomy-treated tooth will be prepared to receive a full-coverage stainless steel crown (SSC) after the procedure.
  • Measuring Cytokines levelOther

    measuring cytokines level as an indicator for pulp inflammation

Study groups in NCT07171229
Study groupRoleWhat they receive
occlusal decayExperimentalPrimary molars diagnosed with reversible pulpits caused by occlusal decay
Receives: Procedure: Pulpotomy; Other: Measuring Cytokines level
Proximal decayActive comparatorPrimary molars diagnosed with reversible pulpits caused by Proximal decay.
Receives: Procedure: Pulpotomy; Other: Measuring Cytokines level

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post operative Pain

    The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    Ask the patient to rate their current level of pain by placing a mark on the line. Use a ruler to measure the distance in centimetres from the 'no pain marker' (or zero) to the current pain mark. This provides a pain intensity score out of 10; for example, 6 out of 10 (or 6/10).

    Measured: pain will be measured at one week , 3 months , 6 months and 12 months.

  2. Preapical lesion

    by Clinical examination: presence of Swelling, sinus tract, or fistula: ,(binary outcome: present or absent )

    Measured: will be measured at 3 months , 6 months and 12 months

  3. Pain on percussion

    Tapping the tooth with the blunt end of the mirror binary outcome: present or absent

    Measured: will be measured at 3 months , 6 months and 12 months

  4. Mobility

    using Miller's mobility test :involves holding the tooth firmly between two instruments and assessing its mobility on a scale from 0 to 3. A score of 0 indicates no detectable movement, while scores of 1-3 represent increasing degrees of mobility.

    it will be measured as present for any score from 1 to 3 (binary: present or absent)

    Measured: will be measured at 3 months , 6 months and 12 months

Secondary outcomes (2)
  1. radiographic success

    using Digital periapical intraoral radiograph

    Radiographic Success:

    • Radiolucency at the furcation or periapical area, internal or external root resorption, will be examined (present or not) through digital periapical radiographs.

    Criteria for radiographic success

    • No evidence of extensive pathologic root resorption.
    • No evidence of pathological interradicular and/or periapical radiolucency.
    • No evidence of the development of pathologic radiolucency involving the successor tooth germ.

    Measured: baseline data at the first visit following the procedure completion and at 6 and 12 months

  2. Cytokines level

    blood sample will be collected from exposed pulp chamber before removal and IL-8 \& IL-10 levels will be measured using Enzyme-linked immunoassay ( ELISA) kit. unit of measurement: ng/L

    Measured: at the time of pulpotomy procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Sep 2025
  2. Study start1 Sep 2025 (estimated)
  3. Primary completion1 Sep 2026 (estimated)
  4. Study completion1 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
58 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07171229
Sponsor's protocol ID
14422023529314
Status last verified
Sep 2025
First submitted
25 Aug 2025
Last updated
12 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Pulpotomy and Measuring Cytokines level in people with Pulpitis - Reversible and Occlusal Caries, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 12 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Yasmin Ma Khalifa, PhD Candidate (+201000300634, Ymkhalifa1991@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Post operative Pain (time frame: pain will be measured at one week , 3 months , 6 months and 12 months.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in